<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854737</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-000149</org_study_id>
    <nct_id>NCT00854737</nct_id>
  </id_info>
  <brief_title>Cytidine and Omega-3 Fatty Acids in Bipolar Disorder</brief_title>
  <official_title>A Combination of Cytidine and Omega-3 Fatty Acids in Bipolar Disorder: Are There Additive or Synergistic Mood Stabilizing Effects?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3
      fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized,
      parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and
      omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week
      period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids +
      cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo
      supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies examining the effect of omega-3 fatty acids on bipolar depression have had
      mixed results. Some studies have found that omega-3 fatty acids have a positive effect on
      bipolar depression symptoms, while other studies have found no difference between placebo and
      omega-3 fatty acid treatment.

      The variable effects noted with omega-3 fatty acids may be due in part to a real effect with
      limited potency. Larger effects might be achieved by combining agents with synergistic
      effects.

      Cytidine is necessary to form key intermediates in the biosynthesis of the phospholipids
      phosphatidylcholine and phosphatidylethanolamine, which are major components of eukaryotic
      cell membranes. Recent human studies by our group have shown that CDP-choline (a compound
      composed of cytidine and choline) can modify brain phospholipid synthesis in healthy adults
      and may have antidepressant effects (Babb et al., 1996; Babb et al., 2002; Carlezon et al.,
      2002; Renshaw et al., 1999). The combination of omega-fatty acids and the related pyrimidine,
      uridine, was associated with enhanced antidepressant-like activity in rats (Carlezon et al.,
      2005). Thus, the combination of omega-3 fatty acid and cytidine, which is interconverted with
      uridine in the body, may provide a safe and powerful way to treat bipolar disorder,
      especially bipolar depression.

      This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot
      study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with
      bipolar disorder. During the 16 week period of the study, subjects are assigned to one of
      three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids
      supplementation alone, and 3) placebo supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood Rating Scale Scores</measure>
    <time_frame>weekly-biweekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Retention Time</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional recovery</measure>
    <time_frame>weekly-biweekly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acid and cytidine supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omega-3 fatty acid supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placeno or sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cytidine</intervention_name>
    <description>cytidine (2g po daily for 4 months)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acids</intervention_name>
    <description>omega-3 fatty acids (4g po daily for 4 months)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sugar pill</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>arm 2 and 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bipolar disorder

          -  mood episode within past year

          -  stable medication regimen

        Exclusion Criteria:

          -  primary psychiatric disorder other than bipolar disorder

          -  significant suicide or homicide risk

          -  unstable medical conditions

          -  current or planned pregnancy

          -  lactose intolerance

          -  medications affecting lipid absorption or metabolism

          -  clozapine treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth L Murphy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mclean.harvard.edu</url>
    <description>hospital website with links to research group and studies</description>
  </link>
  <reference>
    <citation>Babb SM, Appelmans KE, Renshaw PF, Wurtman RJ, Cohen BM. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl). 1996 Sep;127(2):88-94.</citation>
    <PMID>8888372</PMID>
  </reference>
  <reference>
    <citation>Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, Renshaw PF. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002 May;161(3):248-54. Epub 2002 Mar 22.</citation>
    <PMID>12021827</PMID>
  </reference>
  <reference>
    <citation>Carlezon WA Jr, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry. 2005 Feb 15;57(4):343-50.</citation>
    <PMID>15705349</PMID>
  </reference>
  <reference>
    <citation>Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999 May;56(5):407-12.</citation>
    <PMID>10232294</PMID>
  </reference>
  <reference>
    <citation>Carlezon WA, Pliakas AM, Parow AM, Detke MJ, Cohen BM, Renshaw PF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry. 2002 Jun 1;51(11):882-9.</citation>
    <PMID>12022961</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Beth L. Murphy MD, PhD</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>bipolar depression</keyword>
  <keyword>bipolar mania</keyword>
  <keyword>manic depression</keyword>
  <keyword>depression</keyword>
  <keyword>mania</keyword>
  <keyword>hypomania</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

